Literature DB >> 16849370

The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation.

Ji-Hyun Chung1, Michael C Ostrowski, Todd Romigh, Takeo Minaguchi, Kristin A Waite, Charis Eng.   

Abstract

PTEN, a tumor suppressor phosphatase that dephosphorylates both protein and lipid substrates, is mutated in both heritable and sporadic breast cancer. Until recently, PTEN-mediated cell cycle arrest and apoptosis were thought to occur through its well-documented cytoplasmic activities. We have shown that PTEN localizes to the nucleus coincident with the G0-G1 phases of the cell cycle and that compartmentalization may regulate cell cycle progression dependent upon the down-regulation of cyclin D1. However, the mechanism for cyclin D1-dependent growth suppression by nuclear PTEN has remained largely undefined. Utilizing MCF-7 Tet-Off breast cancer cell lines stably expressing two different nuclear localization defective PTEN mutants, as well as wild-type PTEN and empty vector control cells, we demonstrate that nuclear PTEN down-regulates cyclin D1 transcription and this event is mediated by the down-regulation of MAPK specifically by nuclear localized PTEN. These results provide further evidence that nuclear PTEN plays a role through cell cycle suppression functions in regulating carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849370     DOI: 10.1093/hmg/ddl177

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  43 in total

1.  Nuclear PTEN deficiency causes microcephaly with decreased neuronal soma size and increased seizure susceptibility.

Authors:  Atsushi Igarashi; Kie Itoh; Tatsuya Yamada; Yoshihiro Adachi; Takashi Kato; Daisuke Murata; Hiromi Sesaki; Miho Iijima
Journal:  J Biol Chem       Date:  2018-05-07       Impact factor: 5.157

Review 2.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Different effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion.

Authors:  Xiaomu Qiao; Isabelle Roth; Eric Féraille; Udo Hasler
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 4.  PTEN in DNA damage repair.

Authors:  Mei Ming; Yu-Ying He
Journal:  Cancer Lett       Date:  2012-01-18       Impact factor: 8.679

5.  PTEN modulates gene transcription by redistributing genome-wide RNA polymerase II occupancy.

Authors:  Ata Abbas; Roshan Padmanabhan; Todd Romigh; Charis Eng
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

6.  Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

Authors:  Yazhini Ravi; Karuppaiyah Selvendiran; Sarath Meduru; Lucas Citro; Shan Naidu; Mahmood Khan; Brian K Rivera; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2013-11       Impact factor: 2.194

7.  Zona occludens-2 inhibits cyclin D1 expression and cell proliferation and exhibits changes in localization along the cell cycle.

Authors:  Rocio Tapia; Miriam Huerta; Socorro Islas; Antonia Avila-Flores; Esther Lopez-Bayghen; Jörg Weiske; Otmar Huber; Lorenza González-Mariscal
Journal:  Mol Biol Cell       Date:  2008-12-03       Impact factor: 4.138

8.  ΔNp63α promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.

Authors:  Ting Hao; Ye-Hua Gan
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

9.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

10.  Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.

Authors:  Glenn P Lobo; Kristin A Waite; Sarah M Planchon; Todd Romigh; Najah T Nassif; Charis Eng
Journal:  Hum Mol Genet       Date:  2009-05-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.